RG 6180

Drug Profile

RG 6180

Alternative Names: RG6180

Latest Information Update: 11 Feb 2017

Price : $50

At a glance

  • Originator BioNTech
  • Class Antineoplastics; Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Cancer (Parenteral) (Roche Presentation, February 2017)
  • 21 Sep 2016 Preclinical trials in Cancer in Germany (Parenteral)
  • 21 Sep 2016 BioNTech enters into an agreement with Genentech for the development of mRNA cancer vaccines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top